Funded by the European Union’s Horizon 2020 research and innovation programme, MaxONCO is a 2.5 year research and innovation project. The aim of project is to conduct  two Phase II clinical trials and the technology transfer for the manufacturing process of MaxONCO.

News

MaxiVAX awarded €2,785,000 European Commission grant and announces successful closing of its Series B 2 round for an amount of CHF 5 million.

Read more

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 880194